Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2023 | Speech biomarkers for cognitive decline detection

Current assessments of cognitive decline are hindered by inter-rater variability, the need for in-clinic assessment, and a lack of expert availability, leading to infrequent assessment. Digital speech assessments are emerging as a promising solution to detect early-stage cognitive impairment. Ram Kinker Mishra, PhD, BioSensics LLC, Newton, MA, delves into the application of speech biomarkers for detecting and monitoring cognitive decline in Alzheimer’s disease using the innovative BioDigit Speech technology. BioDigit Speech is part of the multimodal, remote monitoring system, Biodigit Home, that assesses gait, balance, activity, and speech for accurate and cost effective cognitive decline monitoring. This technology serves as a comprehensive data collection and analysis platform specifically designed for assessing dementia speech symptoms. Patients are provided with a tablet PC for home use, on which they complete a standardized speech task. The recorded speech is analyzed using artificial intelligence, measuring over 40 speech outcomes and generating a score that indicates the individual’s level of cognitive impairment. This technology offers a holistic evaluation of Alzheimer’s disease speech symptoms, making it highly relevant for clinical trials and research. This interview took place at the Clinical Trials on Alzheimer’s Disease (CTAD) congress 2023 in Boston.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Ram Kinker Mishra is an employee of Biosensics LLC, Neston, MA.